The data reported by Izquierdo-Altarejos et al. [30] demonstrate that golexanolone treatment improves motor and non-motor symptoms in the 6-OHDA rat model of PD via the reduction in microglia and astrocyte activation, in the loss of TH, and the decrease in α-synuclein. Here, TH is linked to Parkinson disease.